While the brain acquires resistance to continuous treatment with mGluR5 inhibitor drugs, lasting effects may still arise if dosing occurs intermittently and during a developmental-critical period. Mark Bear, Picower Professor of Neuroscience at MIT, recalls the “eureka moment” 20 years ago when he realized that a severe developmental brain disorder — fragile X syndrome —...
